Charles River Laboratories International, Inc. (CRL)

NYSE: CRL · Real-Time Price · USD
156.99
+4.27 (2.80%)
Sep 18, 2025, 4:00 PM EDT - Market closed
2.80%
Market Cap7.73B
Revenue (ttm)4.03B
Net Income (ttm)-69.23M
Shares Out 49.21M
EPS (ttm)-1.37
PE Ration/a
Forward PE15.50
Dividendn/a
Ex-Dividend Daten/a
Volume715,188
Open155.00
Previous Close152.72
Day's Range153.47 - 157.63
52-Week Range91.86 - 230.02
Beta1.47
AnalystsBuy
Price Target186.64 (+18.89%)
Earnings DateNov 5, 2025

About CRL

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use o... [Read more]

Sector Healthcare
IPO Date Jun 23, 2000
Employees 20,100
Stock Exchange NYSE
Ticker Symbol CRL
Full Company Profile

Financial Performance

In 2024, CRL's revenue was $4.05 billion, a decrease of -1.92% compared to the previous year's $4.13 billion. Earnings were $10.30 million, a decrease of -97.83%.

Financial Statements

Analyst Summary

According to 15 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $186.64, which is an increase of 18.89% from the latest price.

Price Target
$186.64
(18.89% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Charles River Laboratories Announces Chief Financial Officer Transition

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Chief Financial Officer Transition.

2 days ago - Business Wire

Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River collaborates to enhance oncology manufacturing portfolio by advancing development of cell and gene therapies to treat cancer.

7 days ago - Business Wire

Charles River Laboratories International, Inc. (CRL) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Charles River Laboratories International, Inc. (NYSE:CRL) Baird 2025 Global Healthcare Conference September 10, 2025 9:40 AM EDT Company Participants James Foster - Chairman, President & CEO Conferen...

8 days ago - Seeking Alpha

Charles River Laboratories International, Inc. (CRL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Charles River Laboratories International, Inc. (NYSE:CRL) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants James Foster - Chairman, Presiden...

9 days ago - Seeking Alpha

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Baird and Morgan Stanley Conferences.

10 days ago - Business Wire

Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Integration of Akadeum's GMP-grade Human T Cell Leukopak Isolation Kit into Charles River's Cell Therapy Flex Program announced today.

15 days ago - Business Wire

Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River joins EASYGEN to provide 3D screening expertise, supporting the development of a bedside CAR-T manufacturing platform .

23 days ago - Business Wire

Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript

Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.

6 weeks ago - Seeking Alpha

Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing

Charles River Laboratories International Inc. CRL stock is trading lower on Wednesday after the company released second-quarter 2025 earnings.

6 weeks ago - Benzinga

Charles River: Margin Fears Outweigh Solid Q2

Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable. Ongoing risks include regulatory pressure to phase out animal ...

6 weeks ago - Seeking Alpha

Charles River raises profit forecast on growing demand for drug development services

Charles River Laboratories on Wednesday raised its annual profit forecast, betting on growing demand for its drug discovery and development services from drugmakers, sending its shares up more than 4%...

6 weeks ago - Reuters

Charles River Laboratories Announces Second-Quarter 2025 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2025 Results.

6 weeks ago - Business Wire

Charles River Joins Elly's Team to Drive Rare Disease Gene Therapy Development

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--As part of Charles River's Cell & Gene Therapy Accelerator Program, Elly's Team manufactured critical starting materials for a Phase I clinical ...

2 months ago - Business Wire

Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call.

2 months ago - Business Wire

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River today announced a recycling program, developed in partnership with TerraCycle to give new life to single-use plastic cartridges.

3 months ago - Business Wire

Charles River Laboratories to Present at William Blair and Jefferies Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at William Blair and Jefferies Conferences.

3 months ago - Business Wire

Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and CHDI announce an extension of their partnership, having worked together since 2005 to expedite therapies for Huntington's dise...

4 months ago - Business Wire

Charles River Laboratories to Present at Bank of America Health Care Conference

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Bank of America Health Care Conference.

4 months ago - Business Wire

Activist Elliott reaches key agreement with Charles River. Here are three ways to create value

The firm has three possible paths toward value creation at the drug development company.

4 months ago - CNBC

S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments

The S&P 500 broke a two-session losing streak, rising Wednesday as stocks gained ground in volatile trading following the Federal Reserve's decision to keep interest rates unchanged.

4 months ago - Investopedia

Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript

Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2025 Results Conference Call May 7, 2025 9:00 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Ch...

4 months ago - Seeking Alpha

Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization

Charles River Laboratories International Inc CRL stock is trading higher on Wednesday after the company released better than expected first-quarter 2025 earnings.

4 months ago - Benzinga

Charles River Stock Is Having Its Best Day in 13 Years. A Board Shake-Up and Business Review Will Help.

The biotech said its largest investor would conduct a ‘strategic review' as revenue continued to decline.

4 months ago - Barrons

Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More

U.S. equities were little changed at midday as the market awaited the Federal Reserve's interest-rate decision coming this afternoon. The Dow Jones Industrial Average was higher, the Nasdaq was lower,...

Other symbols: DISSMCI
4 months ago - Investopedia

Charles River to add new directors, review business in agreement with Elliott

Charles River Laboratories said on Wednesday it had reached an agreement with activist investor Elliott Investment Management and added four new directors to its board.

4 months ago - Reuters